EGFR and non-small cell lung carcinoma: In the phase III AURA3 trial (NCT02151981), osimertinib was established as the gold standard for second-line treatment in NSCLC patients with EGFR T790M mutation, outperforming chemotherapy in efficacy and safety[12,13].